TABLE 2.

Relationship Between BRAF V600E Alone, TERT Promoter Mutation Alone, or Their Coexistence and Loss of Radioiodine Avidity in Recurrent PTC

	Loss of RAI		Odds ratio
Tumor type and mutation status	n	P	Unadjusted	Adjusted*
All PTC
No mutation	16/53 (30.2)	Reference	1.00	1.00
BRAF V600E alone	45/64 (70.3)	<0.001	5.39 (2.31–13.13)	4.92 (2.07–12.20)
TERT mutation alone	5/9 (55.6)	0.251	2.84 (0.53–16.32)	2.10 (0.28–16.51)
BRAF + TERT mutations	37/38 (97.4)	<0.001	81.04 (11.67–3,559.83)	103.68 (10.77–5,771.67)
CPTC
No mutation	8/36 (22.2)	Reference	1.00	1.00
BRAF V600E alone	39/55 (70.9)	<0.001	8.30 (2.93–25.95)	7.33 (2.54–23.34)
TERT mutation alone	2/3 (66.7)	0.156	6.57 (0.31–427.22)	20.44 (0.22–2,768.33)
BRAF + TERT mutations	32/32 (100.00)	<0.001	136.12 (20.82–+∞)	179.58 (20.97–+∞)

^*Adjusted for patient age and sex.

CPTC = conventional PTC.

TERT promoter mutations here included, collectively, TERT C228T and TERT C250T. Data in parentheses are percentages or 95% CIs.